38314-49-7

Usage

InChI:InChI=1/C17H16ClNO3S/c1-12-4-7-14(8-5-12)23(21,22)19-10-2-3-17(20)15-9-6-13(18)11-16(15)19/h4-9,11H,2-3,10H2,1H3

Upstream product

• 38314-47-5 methyl 4-chloro-2-[N-(3-ethoxycarbonyl)propyl-N-p-toluenesulfonyl]aminobenzoate 
• 5900-58-3 2-amino-4-chloro-benzoic acid methyl ester 
• 98-59-9 p-toluenesulfonyl chloride 
• 116815-03-3 8-chloro-1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one 
• 42087-80-9 methyl 4-chloro-2-nitrobenzoate 
• 6280-88-2 4-chloro-2-nitro-benzoic acid 
• 29247-79-8 N-p-toluenesulfonyl-4-chloro-anthranilic acid methyl ester 
• 143771-90-8 8-Chloro-5-oxo-1-(toluene-4-sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepine-4-carboxylic acid ethyl ester 

Downstream Products

• 351217-37-3 2-(8-chloro-2-imino-6-(4-methyl phenyl sulfonyl)-1,4,5,6-tetrahydro-2H-benzo[b][1,3]thiazolo[4,5-d]azepin-1-yl)-1-phenyl-1-ethen-1-ol 
• 153894-29-2 8-Chloro-6-(toluene-4-sulfonyl)-5,6-dihydro-4H-1-thia-6-aza-benzo[e]azulene-2-carboxylic acid ethyl ester 
• 154890-41-2 8-chloro-5-(N-methylamino)-1-[4-[(2-methylbenzoyl)amino]benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 137977-41-4 8-chloro-1-[4-[(2-methylbenzoyl)amino]benzoyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 137984-93-1 8-chloro-1-(4-nitrobenzoyl)-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 137984-96-4 1-(4-aminobenzoyl)-8-chloro-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 271248-58-9 8-chloro-1-(2-methylbenzoyl)-1,2,3,4-tetrahydro-1-benzazepin-5-one 
• 153894-36-1 8-chloro-6-(4-methylphenyl sulfonyl)-5,6-dihydro-4H-benzo[3,4]cyclohepta[d][1,3]thiazol-2-amine 
• 116815-03-3 8-chloro-1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Synthesis and diuretic activity of bicyclic fused heterocycles containing oxime-O-sulfonic acid moiety

In order to investigate the origin of the loop-type diuretic activity of M17055 (1), several variants (3-9) were designed and synthesized by modifying the quinolinone skeleton, and their diuretic activities were compared with the lead 1 and furosemide in dogs. It was found that the negative charge distribution pattern afforded by the dispositional arrangement of the 4- oxime-O-sulfonic acid and 1-N-acyl carbonyl moiety attached to the tetrahydropyridine ring system is inevitable for the development of the activity, which strongly supports the previously proposed model for the active site of the Na+-K+-2Cl- cotransporter. Also reported is the first synthesis of the dihydrothieno[3,2-b]pyridine-7(4H)-one ring system required in the synthesis of compound 9. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5- tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist

We previously reported a series of benzazepine derivatives as orally active nonpeptide arginine vasopressin (AVP) V2 receptor antagonists. After the lead structure OPC-31260 was structurally evaluated and optimized, the introduction of the 7-Cl moiety on the benzazepine and 2-CH3 on the aminobenzoyl moiety enhanced its oral activity. The new AVP-V2 selective antagonist OPC-41061 was determined to be a potent and orally active agent. Copyright (C) 1999 Elsevier Science Ltd.